Premium
HEALTH‐RELATED QUALITY OF LIFE AMONG PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL) IN A PHASE 3 STUDY OF PEMBROLIZUMAB VERSUS BRENTUXIMAB VEDOTIN
Author(s) -
Zinzani P. L.,
Raut M.,
Saretsky T.,
Ramchandren R.,
Santoro A.,
PaszkiewiczKozik E.,
Gasiorowski R.,
Johnson N. A.,
Oliveira J. S. R.,
Buccheri V.,
Perini G. F.,
Dickinson M.,
McDonald A.,
Ozcan M.,
Sekiguchi N.,
Giezek H.,
Nahar A.,
Kuruvilla J.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.105_2880
Subject(s) - medicine , nausea , quality of life (healthcare) , brentuximab vedotin , pembrolizumab , population , oncology , hodgkin lymphoma , cancer , lymphoma , nursing , environmental health , immunotherapy